TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Turn Therapeutics Inc ( (TTRX) ) has provided an update.
On October 30, 2025, Turn Therapeutics announced a global supply, development, and license agreement with Medline, a leading medical-surgical product manufacturer and distributor. This collaboration aims to leverage Turn’s PermaFusion® delivery platform with Medline’s global distribution capabilities to enhance product opportunities in professional and retail markets. The partnership is seen as a transformative milestone for Turn, enabling the company to focus on innovation while utilizing Medline’s infrastructure to deliver advanced solutions worldwide. Financial terms and development timelines remain confidential, with further updates expected as joint initiatives progress.
More about Turn Therapeutics Inc
Turn Therapeutics is a biotechnology company focused on developing and commercializing products for dermatology, wound care, and infectious disease. The company has received FDA clearances for its wound and dermatology formulations and is advancing clinical programs in eczema and onychomycosis. Additionally, Turn is involved in global health initiatives for thermostable vaccine delivery to underserved areas.
Average Trading Volume: 1,508,081
See more data about TTRX stock on TipRanks’ Stock Analysis page.